Literature DB >> 2889677

Lack of correlation between rare Ha-ras alleles and urothelial cancer in Japan.

J Ishikawa1, S Maeda, R Takahashi, S Kamidono, T Sugiyama.   

Abstract

Restriction fragment length polymorphism (RFLP) of Ha-ras gene was surveyed by Southern blot analysis in leukocyte DNA from 55 normal individuals and 58 urothelial cancer patients in Japan. Three common alleles and 4 rare alleles were classified. The frequency of common alleles in normal Japanese individuals differed from that in Caucasians previously reported; a 7.2-7.5-kb BamHI fragment of common allele was not observed in Japanese individuals. No significant increase in frequency of the rare Ha-ras allele was observed in the group of cancer patients. Moreover, no significant difference in frequency was observed for the 3 common alleles. Tumor DNA was compared with leukocyte DNA in 30 urothelial cancer patients: in 3 of 8 cases with heterozygous Ha-ras locus, decreased intensity of one band, indicating partial loss of one allele in tumor DNA, was observed. In 3 tumors with either deletion of one Ha-ras allele or a rare Ha-ras allele, expression of Ha-ras gene was examined by Northern blot analysis. Such genetic alterations did not always result in a marked increase in Ha-ras expression. These data suggest that these genetic alterations are not directly related to Ha-ras expression, and that RFLP of Ha-ras gene is not a useful genetic marker for urothelial cancer. On the other hand, deletion of one Ha-ras allele was observed in 1 of 5 cases of bladder cancer and in 2 of 3 cases of renal pelvic cancer, suggesting that that deletion may be important in the development of urothelial cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889677     DOI: 10.1002/ijc.2910400407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Minisatellite allele diversification: the origin of rare alleles at the HRAS1 locus.

Authors:  A Kasperczyk; N A DiMartino; T G Krontiris
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

2.  Fundamental study on the mechanism of DNA degradation in tissues fixed in formaldehyde.

Authors:  Y Tokuda; T Nakamura; K Satonaka; S Maeda; K Doi; S Baba; T Sugiyama
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

3.  TaqI polymorphism within the c-Ha-ras-1 VTR is associated with melanoma.

Authors:  N K Hayward; D J Nancarrow; P G Parsons; C Kidson; K A Ellem
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

4.  Distribution of Ha-ras alleles in patients with colorectal cancer and Crohn's disease.

Authors:  R Klingel; P Mittelstaedt; W G Dippold; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

5.  Population genetics of the HRAS1 minisatellite locus.

Authors:  B Devlin; T Krontiris; N Risch
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

6.  Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor.

Authors:  I Zborovskaya; A Gasparian; M Kitaeva; B Polotzky; N Tupitzin; Z Machaladze; S Gerasimov; M Shtutman; M Jakubovskaya; M Davidov; A Tatosyan
Journal:  Clin Exp Metastasis       Date:  1996-11       Impact factor: 5.150

7.  Analysis of Ha-ras 1 allele frequencies in hereditary non-polyposis colorectal cancer.

Authors:  P Jeevaratnam; P J Browett; N S Van de Water; J R Jass
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

8.  Ha-ras-1 alleles in Norwegian lung cancer patients.

Authors:  D Ryberg; T Tefre; S Ovrebø; V Skaug; L Stangeland; A Naalsund; R Baera; A L Børresen; A Haugen
Journal:  Hum Genet       Date:  1990-11       Impact factor: 4.132

9.  Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis.

Authors:  A Weston; N E Caporaso; L S Perrin; H Sugimura; S Tamai; T G Krontiris; B F Trump; R N Hoover; C C Harris
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.